ABIVAX (EPA:ABVX) | WebDisclosure

Basculer en Français

9784	Companies
196006	Keywords
127065	Articles
104238	Press releases

Home
Companies
ABIVAX

PRESS RELEASE

published on 07/23/2025 at 22:15, 6 months 10 days ago

Abivax Announces Launch of Public Offering
Abivax announces launch of $400 million public offering to fund therapeutics for chronic inflammatory diseases. Underwritten by Leerink Partners, Piper Sandler, Guggenheim Securities, with LifeSci Capital, BTIG, Van Lanschot Kempen as managers

Biotechnology Financing Abivax Underwriters Public Offering
BRIEF

published on 07/22/2025 at 22:10, 6 months 11 days ago

Abivax Announces Positive Phase 3 Results for Obefazimod in Ulcerative Colitis

Abivax Obefazimod Ulcerative Colitis Phase 3 Trials MiR-124 Enhancer
BRIEF

published on 07/22/2025 at 22:10, 6 months 11 days ago

Abivax annonce des résultats positifs de phase 3 pour l'obéfazimod dans la rectocolite hémorragique

Abivax Obefazimod Rectocolite Hémorragique Essais De Phase 3 Amplificateur MiR-124
PRESS RELEASE

published on 07/22/2025 at 22:06, 6 months 11 days ago

Abivax annonce des résultats positifs de phase 3 pour les deux essais d'induction ABTECT de 8 semaines, évaluant obefazimod dans le traitement de la rectocolite hémorragique
Abivax annonce des résultats positifs de phase 3 pour les essais ABTECT évaluant obefazimod dans la rectocolite hémorragique. Conférence prévue

Abivax Obefazimod Rectocolite Hémorragique Phase 3 Résultats Positifs
PRESS RELEASE

published on 07/22/2025 at 22:06, 6 months 11 days ago

Abivax annonce des résultats positifs de phase 3 pour les deux essais d'induction ABTECT de 8 semaines, évaluant obefazimod dans le traitement de la rectocolite hémorragique
Abivax annonce des résultats positifs de phase 3 pour les essais d'induction ABTECT de 8 semaines, évaluant obefazimod dans le traitement de la rectocolite hémorragique. Résultats de top-line prometteurs

Abivax Obefazimod Rectocolite Hémorragique Phase 3 Top-line
PRESS RELEASE

published on 07/22/2025 at 22:05, 6 months 11 days ago

Abivax Announces Positive Phase 3 Results from Both ABTECT 8-Week Induction Trials Investigating Obefazimod, its First-in-Class Oral miR-124 Enhancer, in Moderate to Severely Active Ulcerative Colitis
Abivax announces positive Phase 3 results for obefazimod in ulcerative colitis trials, meeting key endpoints and demonstrating favorable tolerability. Conference call scheduled for more insights

Abivax Obefazimod Ulcerative Colitis Clinical Trials Phase 3 Results
BRIEF

published on 07/17/2025 at 18:05, 6 months 16 days ago

ABIVAX : Détails sur le capital social et les droits de vote

Nombre D'actions Droits De Vote Capital Social Abivax Investisseurs
BRIEF

published on 07/17/2025 at 18:05, 6 months 16 days ago

ABIVAX: Details on share capital and voting rights

Share Capital Voting Rights Investors Abivax Number Of Shares
PRESS RELEASE

published on 07/17/2025 at 18:00, 6 months 16 days ago

ABIVAX: Nombre d’actions composant le capital social et nombre total de droits de vote
ABIVAX communique le nombre d'actions composant son capital social et le nombre total de droits de vote conformément aux dispositions réglementaires

Droits De Vote Capital Social Abivax Information Réglementaire Société Biotechnologie
BRIEF

published on 06/19/2025 at 18:05, 7 months 13 days ago

ABIVAX Déclare la Composition de son Capital Social et Droits de Vote

Euronext Paris Droits De Vote Capital Social Abivax Réglementation AMF

Accesswire

Published on 02/02/2026 at 23:55, 3 hours 36 minutes ago

2026 Tunkillia Development Drilling Programs Begin
Published on 02/02/2026 at 23:55, 3 hours 36 minutes ago

55 North Mining Announces Winter Exploration Drill Program at Last Hope Gold Project
Published on 02/02/2026 at 23:25, 4 hours 6 minutes ago

Western Announces Sale of GlassMasters Investment
Published on 02/02/2026 at 22:05, 5 hours 26 minutes ago

Organto Foods to Attend Fruit Logistica 2026 in Berlin, Germany From February 4-6, 2026
Published on 02/02/2026 at 15:00, 12 hours 31 minutes ago

Jericho Energy Ventures Strategically Terminates SmartKem LOI to Advance Independent Data Center Energy Infrastructure Platform

View all ACCESSWIRE

EQS Group

Published on 02/02/2026 at 20:00, 7 hours 30 minutes ago

CGTN AMERICA & CCTV UN: Cultural Event Celebrating the Spring Festival and the 55th Anniversary of China-U.S. Ping-Pong Diplomacy
Published on 02/02/2026 at 19:57, 7 hours 33 minutes ago

US federal court grants preliminary injunction allowing Sunrise Wind construction to resume
Published on 02/02/2026 at 19:42, 7 hours 48 minutes ago

EQS-Adhoc: ProSiebenSat.1 publishes preliminary figures for financial year 2025
Published on 02/02/2026 at 19:05, 8 hours 25 minutes ago

Virtual Science AI launches the life science industry's first medical congress AI solution for real-time event conversational intelligence
Published on 02/02/2026 at 19:00, 8 hours 31 minutes ago

PATRIMOINE ET COMMERCE: INFORMATIONS RELATIVES AU NOMBRE TOTAL DE DROITS DE VOTE ET AU NOMBRE D’ACTIONS COMPOSANT LE CAPITAL SOCIAL AU TITRE DE L’ARTICLE 223-16 DU REGLEMENT GENERAL DE L'AMF

Les Echos

Published on 02/02/2026 at 18:23, 9 hours 7 minutes ago

Monthly disclosure of the total number of shares and voting rights - January 2026
Published on 02/02/2026 at 18:23, 9 hours 7 minutes ago

TF1 - Déclaration mensuelle des actions et droits de vote - Janvier 2026
Published on 02/02/2026 at 18:00, 9 hours 31 minutes ago

Covivio - Information on total number of voting rights and share capital
Published on 02/02/2026 at 18:00, 9 hours 31 minutes ago

Covivio Hotels - Informations relatives au nombre total de droits de vote et d’actions composant le capital social
Published on 02/02/2026 at 18:00, 9 hours 31 minutes ago

Covivio - Informations relatives au nombre total de droits de vote et d’actions composant le capital social

View all LES ECHOS COMFI WIRE